OST Complex Inhibitors for Dengue Virus Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies and vaccines for dengue virus infection are inadequate, with no effective treatment available and incomplete protection against the four antigenically distinct serotypes, and there is a lack of understanding about the host cell factors involved in dengue virus replication.
Innovation Solution
Development of inhibitors targeting the OST complex, CCT complex, and RACK1 to disrupt their functions, which are essential for dengue virus replication, using compounds such as NGI-1, antibodies, aptamers, or siRNAs that specifically target these complexes to inhibit their activity without cytotoxic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies and vaccines are used for dengue virus infection, then treatment and prevention are provided, but the protection is incomplete against the four antigenically distinct serotypes and no effective treatment is available
Solution Approach 1:
The patent extracts and targets specific host cell factors (OST complex, CCT complex, RACK1) that are essential for dengue virus replication across all four serotypes. By inhibiting these conserved host factors rather than targeting variable viral components, the invention achieves broad-spectrum effectiveness against all DENV serotypes with a single therapeutic approach.
2Reliability
If inhibitors targeting host factors are developed to block virus replication, then antiviral activity is achieved, but potential cytotoxic effects on host cells may occur
Solution Approach 1:
The patent employs siRNA-mediated knockdown rather than complete inhibition of host factors, achieving sufficient reduction in factor function to block viral replication while maintaining enough residual activity to preserve normal cellular functions and avoid cytotoxicity.
Solution Approach 2:
The invention uses siRNA as an intermediary molecule that indirectly inhibits host factors involved in viral replication. This indirect mechanism allows for more controlled and reversible inhibition compared to direct targeting, reducing the risk of severe cytotoxic effects while maintaining antiviral activity.
3Loss of information
If comprehensive understanding of host cell factors in dengue virus replication is achieved, then effective therapeutic targets are identified, but extensive research and characterization are required
Solution Approach 1:
The patent identifies host cell factors (OST complex, CCT complex, RACK1) that serve multiple functions: they are involved in dengue virus replication across all four serotypes, and their inhibition provides a unified therapeutic strategy. This multi-functional targeting accelerates therapeutic development by providing a single approach that addresses multiple aspects of viral pathogenesis.
Data Source
AI summary
The present invention relates to the treatment of Dengue virus infection. To gain insight into the molecular and cellular function of the DENV RC, the inventors generated a tagged NS1 DENV replicon in order to identify associated host proteins during active viral replication. This allowed an unprecedented mapping of the NS1-host interactome in a relevant system and the identification of cellular modules targeted by the DENV RC. By combining these proteomics data with gene silencing experiments, they identified a set of Host Dependency Factors (HDFs) and Host Restriction Factors (HRFs) that critically impact DENV infection. More they tested the NGI-1 molecule for its OST complex inhibition properties and showed that this molecule can be used to treat Dengue virus infection. Thus, the invention relates to an inhibitor of the OST complex and/or of the CCT complex and/or of RACK1 for use in the treatment of dengue virus infection in a subject in need thereof.